AdvanCell

📍 Boston, United States🗓 Founded 2019👥 100 employees💰 Last funded Jun 2026
Biotechnology Research🌐 advancell.com.au
Website LinkedIn
AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Hong Kong SAR
1
Frequently asked questions
Who invested in AdvanCell?
AdvanCell has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did AdvanCell last raise funding?
The most recent investment in AdvanCell recorded on gritt.io was in June 2026.
When was AdvanCell founded?
AdvanCell was founded in 2019.
What industry is AdvanCell in?
AdvanCell operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AdvanCell based?
AdvanCell is headquartered in Boston, United States.